"Janus Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
| Descriptor ID |
D053614
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.200 D12.776.476.393.200 D12.776.624.664.700.117
|
| Concept/Terms |
Janus Kinase 2- Janus Kinase 2
- JAK-2 Protein Tyrosine Kinase
- JAK 2 Protein Tyrosine Kinase
- JAK2 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 2".
This graph shows the total number of publications written about "Janus Kinase 2" by people in this website by year, and whether "Janus Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 2 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 4 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 1 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 2" by people in Profiles.
-
Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy. Clin Cancer Res. 2025 Feb 03; 31(3):588-602.
-
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. Am J Clin Pathol. 2024 Sep 03; 162(3):233-242.
-
Determinants of mosaic chromosomal alteration fitness. Nat Commun. 2024 May 07; 15(1):3800.
-
Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023 04; 127:107033.
-
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 06; 18(3):41-55.
-
Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
-
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023 01; 98(1):166-179.
-
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 2022 09 15; 140(11):1291-1304.
-
Subcutaneous Atezolizumab: A Jab Without a Benefit. Clin Pharmacol Drug Dev. 2022 01; 11(1):134-135.
-
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv. 2021 09 14; 5(17):3492-3496.